Regulatory Clampdown Sends Shockwaves Through Telehealth Provider Hims & Hers

The telehealth sector, known for its rapid digital innovation, is facing increased regulatory scrutiny. Hims & Hers Health, Inc., a prominent player in the space, finds itself at the center of a significant challenge from the U.S. Food and Drug Administration (FDA), creating uncertainty for its stock performance.

FDA Issues Stern Warning Over Weight Loss Drug Claims

In a recent formal warning letter, the FDA has accused Hims & Hers of promoting its compounded semaglutid products with claims it deems “false or misleading.” The regulatory body took specific issue with the company’s marketing language, which included statements that the products contain the “same active ingredient as Ozempic and Wegovy” and feature “clinically proven ingredients.”

The FDA’s communication was unequivocal, stating that “compounded drugs are not FDA-approved.” It argued that such assertions create a misleading impression for consumers, suggesting these offerings are equivalent to the agency-approved medications, which is not the case.

This action was not isolated. The warning was part of a broader initiative by the FDA, which saw approximately 100 similar letters dispatched to various pharmaceutical and telehealth companies, aligning with an executive order targeting deceptive drug advertising.

Market Experts Offer Divergent Views

The regulatory pressure has elicited a mixed response from financial analysts. BTIG has reaffirmed its “Buy” rating on the stock, projecting a price target of $85 and suggesting a potential upside of roughly 50 percent. The firm’s optimism is rooted in Hims & Hers’ strong subscriber growth in segments beyond weight management and the continued expansion of its core telehealth services, which it views as powerful growth engines.

Should investors sell immediately? Or is it worth buying Hims & Hers?

This bullish stance, however, contrasts with the broader analyst consensus. A survey of 13 market experts shows an average rating of “Hold” for the shares, accompanied by a more conservative price target of $48.67.

Company Faces Tight Deadline and Potential Consequences

Hims & Hers now operates under a strict 15-business-day deadline to formulate a formal response to the FDA’s allegations. The company is required to either correct the cited violations or provide evidence demonstrating that its products are in full compliance with federal law. A failure to adequately address the concerns could result in severe legal repercussions, including product seizures and court-ordered injunctions.

In response to the situation, company spokesperson Javier Lacayo expressed a commitment to collaboration, stating they look forward to “working with the FDA to resolve all concerns.” He emphasized that the weight loss medications are produced in “industry-leading facilities” using ingredients sourced from FDA-regulated suppliers and are subject to “rigorous quality testing.”

A Core Business Segment Under Threat

The timing of this regulatory challenge is critical for the company. Weight loss medications have become a substantial revenue stream, generating $420 million in the first half of 2025 alone. This segment forms a significant part of the company’s overall business model. With a subscriber base of 2.4 million, any enforced restrictions on the promotion or sale of these products could materially hinder future growth prospects.

This regulatory cloud arrives even as the company’s operational performance remains robust. For the second quarter of 2025, Hims & Hers reported a 73 percent surge in revenue, reaching $544.8 million, while its net profit tripled to $42.5 million.